Molecular Vision: Liao, Mol Vis 2025; 31:515-524. Table 2

Table 2. Drug-gene network analysis.

Gene	Drug	Interaction score (0-6) ^#	Gene relevance to ROP (%) ^#	Drug relevance to retinopathy (%) ^#	Combined Correlation (%) ^#
HMOX1	STANNSOPORFIN	5.800422062	0.78	0.65	0.72
HMOX1	RECOMBINANT NEUROTROPHIC FACTOR	2.320168825	0.78	0.5	0.67
HMOX1	ZINC CHLORIDE	2.320168825	0.78	0.4	0.63
ALB	COCHINCHINENIN C	2.372899934	0.42	0.3	0.36
ALB	CHEMBL:CHEMBL1945287	2.372899934	0.42	0.25	0.35
JUN	NEOCHAMAEJASMIN A	2.269730372	0.68	0.35	0.55
JUN	BRUCEANTIN	2.269730372	0.68	0.3	0.53
JUN	IRISOLIDONE	2.269730372	0.68	0.55	0.62
JUN	CHEMBL:CHEMBL477052	2.269730372	0.68	0.2	0.48
JUN	SERGEOLIDE	2.269730372	0.68	0.15	0.45

Interaction scores for the drug-gene pairs were derived from the DGIdb database and were calculated by integrating drug-target affinity (scored 0-3) with gene-disease association strength (scored 0-3). Scores of ≥4 indicated high-confidence interactions, scores between 2 and 4 suggested moderate evidence, and scores <2 reflected minimal support. Gene relevance (%) was derived from the log2 fold change in the ROP dataset (GSE135844). Drug relevance (%) was based on DrugBank annotations and PubMed-reviewed mechanisms. The Combined Correlation (%) was a weighted score based on target priority (gene contribution: 60%; drug contribution: 40%).